What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
about
Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagusThree-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.Barrett's esophagus and the increasing role of endoluminal therapy.Photodynamic therapy of cancer: an updatePhotodynamic therapy for Barrett's esophagus with high-grade dysplasia.Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett's esophagus who have elevated genomic instabilityLong-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus.Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.A cost-utility analysis of ablative therapy for Barrett's esophagus.Photodynamic therapy for Barrett's esophagus: does light still have a role?Endoscopic therapies for Barrett's-associated dysplasia: a new paradigm for a new decade.Management of early-stage esophageal neoplasia (MESEN) consensus.Endoscopic versus surgical therapy for Barrett's esophagus neoplasia.Endoscopic mucosal resection: early experience in British Columbia.Endoscopic Mucosal Resection as the Primary Treatment for Barrett Esophagus With Dysplasia.The impact of flexible endoscopy in esophageal surgery.Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus.Endoscopic therapy for Barrett's esophagus and early esophageal cancer: Where do we go from here?
P2860
Q24202793-1D7451FE-A329-4219-A3E6-B6B31BCAC945Q33326627-C1BA15FC-5DE8-4FA2-93DF-89E1A7370A7FQ34408906-9B555AB9-152B-4DB9-936D-CB4FCC6DA9BDQ35532394-DF1CEE11-2E3E-444F-B5F1-48C3AA2DB41AQ36131795-5C6F6A63-61F4-4A9D-9EEC-445974AA9847Q36921955-2D05DAC1-D9C2-49B5-A676-CED302ED6C97Q37106236-C10316C1-D7CB-4CA7-ADE2-2CF55C724787Q37133451-A7AE9DFD-08BA-48F5-9E22-2E0248D053D0Q37219864-47E2833B-5703-4506-9A94-42668A0128CDQ37344276-36E11C84-45CC-4E4E-BC4F-9F41889E211CQ38014493-F7215FDC-01B0-44D5-9A15-74D518BB6D87Q38150209-36280C2D-11C4-479A-A8CE-16629D5BBF7FQ38243713-1D0F757D-838E-4A56-A23B-AF2EBB1B40D2Q40367247-E90E53DB-4F94-4140-9F86-2F049FFEDB56Q40767513-8E4209D5-3CE3-4B4F-8484-7D4AF6637B8DQ41202627-1D25D370-8768-45B0-995D-58A1E6CEF018Q48794382-375F0C44-BA37-4688-83BE-26DFF52E3164Q57074640-8EA443D9-4080-4A36-BC23-F0BFDA085E1C
P2860
What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
What is the best management st ...... A cost effectiveness analysis.
@en
What is the best management st ...... A cost effectiveness analysis.
@nl
type
label
What is the best management st ...... A cost effectiveness analysis.
@en
What is the best management st ...... A cost effectiveness analysis.
@nl
prefLabel
What is the best management st ...... A cost effectiveness analysis.
@en
What is the best management st ...... A cost effectiveness analysis.
@nl
P2093
P2860
P356
P1433
P1476
What is the best management st ...... A cost effectiveness analysis.
@en
P2093
B F Overholt
N J Shaheen
P2860
P304
P356
10.1136/GUT.2003.033837
P407
P50
P577
2004-12-01T00:00:00Z